May 20, 2025
11 a.m. EDT
The global obesity epidemic has driven demand for innovative treatments, creating a competitive and rapidly evolving landscape in obesity drug development. While media coverage has amplified interest and sensationalized the use of GLP-1 receptor agonists, gaps remain in addressing unmet needs and improving current approved treatments for patients1.
This webinar will explore the obesity drug landscape, highlighting how the industry is responding to leading therapies and identifying opportunities for future innovation. We will discuss alternative mechanisms of action that expand therapeutic possibilities beyond GLP-1 receptor agonists, offering hope for more effective solutions.
Additionally, our expert will examine critical operational challenges in obesity drug clinical trials, including recruitment hurdles, psychological barriers, and the importance of holistic patient support. By integrating psychological care and addressing social stigmas, we can improve trial retention and elevate the standard of care for patients managing obesity.
Join us to navigate the evolving obesity treatment landscape, uncover practical solutions to trial challenges, and pave the way for more effective therapies.
Attendees will gain insights into:
- Overview of FDA-approved and investigational obesity drugs
- Novel mechanisms of action being explored in obesity drug research
- Ways to overcome hurdles in obesity clinical trials
Speaker:
Ana Gonzalez-Santis, PhD, PMP, Executive Director, Program Strategy, General Medicine
Source:
- An analysis of national news coverage of semaglutide for weight loss
Gionfriddo, Michael R. et al.
Journal of the American Pharmacists Association, Volume 65, Issue 1, 102297
Perspectives Blog 